Drugs / Efgbemalenograstim alfa

Trials 1

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06143735 Dec 2023 → Dec 2024 non-small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2025-03-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results “头对头”试验!艾贝格司亭α长效升白再添新证 cttq.com ↗
研究结果显示,艾贝格司亭α在预防化疗引起的中性粒细胞减少症(CIN)的临床试验中,非劣效于培非格司亭,且在后续化疗周期中表现出更低的严重中性粒细胞减少发生率[1]。

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Efgbemalenograstim alfa ClinicalTrials.gov intervention name — accepted as the source's own label NCT06143735 ↗
Known as Efbemalenograstim alfa “Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of...” NCT06143735 ↗
Modality Protein / enzyme biologic “is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2)” NCT06143735 ↗
Route Subcutaneous “subcutaneous injection” NCT06143735 ↗